PERRIGO COMPANY |
||||
FY 2013 AND ROSEMONT GUIDANCE |
||||
RECONCILIATION OF NON-GAAP MEASURES |
||||
(unaudited) |
||||
Full Year |
||||
Fiscal 2013 Guidance |
||||
FY13 reported diluted EPS range (2) |
$4.67 - $4.87 |
|||
Deal-related amortization (1,2) |
0.68 |
|||
Charge associated with inventory step-up (2) |
0.11 |
|||
Charges associated with acquisition and severance costs(2) |
0.05 |
|||
Loss on sale of investment |
0.02 |
|||
FY13 adjusted diluted EPS range |
$5.53 - $5.73 |
|||
(1) Amortization of acquired intangible assets related to business combinations and asset acquisitions | ||||
(2) Includes estimate for the February 11, 2013 acquisition of Rosemont Pharmaceuticals Ltd. but does | ||||
not include any estimate related to the Velcera Inc. acquisition |
||||
First 12 Months Accretion |
||||
Post-Closing Rosemont |
||||
Rosemont accretion first 12 months post-close - reported diluted EPS |
$0.02 |
|||
Deal-related amortization (1) |
0.13 |
|||
Charge associated with inventory step-up |
0.06 |
|||
Charges associated with acquisition-related costs |
0.03 |
|||
Rosemont accretion first 12 months post-close - adjusted diluted EPS |
$0.24 |
|||
(1) Amortization of acquired intangible assets related to business combinations and asset acquisitions |